Rapamycin Reference

Plain English

What it is

Rapamycin (also called sirolimus) is a prescription drug that quiets the immune system by blocking a cell-growth pathway called mTOR. The FDA approved it as Rapamune to help stop the body from rejecting a transplanted kidney, and as a skin gel called Hyftor for facial bumps caused by a genetic condition called tuberous sclerosis.

What people use it for

In the longevity-research community, some people use it off-label hoping to slow aging or stay healthier longer. That anti-aging use is not FDA-approved and is not proven in people.

What the science shows

In mice, rapamycin reliably extended lifespan across repeated experiments, even when treatment began late in life, by roughly ten to twenty percent. Human evidence is much thinner. A few small studies on immune aging plus a one-year pilot trial called PEARL found low, intermittent amounts relatively safe with small gains in muscle mass and self-reported well-being, but these are short-term markers, not proof of a longer or healthier life.

The catch

This is a powerful prescription immune-suppressing drug, not a casual supplement. Its label carries a warning that it can raise the risk of serious infections and of lymphoma and other cancers, and it commonly causes high blood fats and cholesterol, high blood pressure, swelling, mouth sores, and slower wound healing. The anti-aging use has no large outcome trial in healthy people and is a prescriber-led decision that comes with real lab monitoring.

Reference summary

NIA Interventions Testing Program (Harrison 2009 Nature, Miller 2014 Aging Cell) showed reproducible mouse-lifespan extension on the order of 10-20 percent at typical doses, with roughly 23 percent in males and 26 percent in females at the threefold-higher dose in Miller 2014. Human data are limited to small rapalog immune-aging trials (Mannick 2014, 2018) and the PEARL trial (NCT04488601), whose one-year results (reported 2024 to 2025) found intermittent low-dose rapamycin safe with modest gains in lean mass and self-reported well-being but no lifespan benefit - all surrogate endpoints. No Phase 3 outcome trial in healthy adults exists.

Regulatory and posture

Categories

Longevity

Aliases

Sirolimus, Rapamune, Hyftor, mTOR inhibitor (small molecule, not a peptide)

Evidence posture

human - Off-label longevity use is investigational; no Phase 3 outcome trial in healthy adults.

Regulatory status

FDA-approved as Rapamune (1999) for prophylaxis of organ rejection in kidney transplantation, and as topical Hyftor (2022) for facial angiofibromas of tuberous sclerosis complex. Off-label longevity use is not FDA-approved and is investigational.

Content review status

label verified